3D Systems Earnings Call Transcripts
Fiscal Year 2026
-
Management highlighted a strategic refocus on core 3D printing, divestitures, and investments in healthcare and aerospace/defense. FDA-approved dentures and advanced metal printing are set to drive future growth, with cost actions and a strengthened balance sheet positioning for improved profitability by 2026.
Fiscal Year 2025
-
Sequential revenue growth and cost reductions drove a stronger Q4 and improved EBITDA, despite full-year revenue declines due to macro headwinds. Key growth markets—A&D, PHS, and dental—delivered double-digit growth, with further expansion and margin improvement expected in 2026.
-
Revenue declined year-over-year due to macroeconomic headwinds and lower dental sales, but cost reduction initiatives and new product launches in healthcare and industrial segments are driving improved margins and future growth prospects. Strategic partnerships and international expansion support long-term opportunities.
-
Q2 2025 revenue fell 16% year-over-year due to macro and tariff headwinds, but sequential growth and strong medtech and aerospace performance signal stabilization. Aggressive restructuring, cost reductions, and new product launches position the company for profitability and growth in 2026.
-
Q1 2025 revenue declined 8% year-over-year to $95 million, with materials sales down 23% and gross margin falling to 35%. Aggressive cost reductions totaling $70 million are underway, and 2025 guidance was withdrawn due to ongoing tariff and CapEx uncertainty. Cash position strengthened to $250 million post-Geomatic sale.
-
3D printing is driving rapid transformation in dental and healthcare markets, with new products and a major Align contract fueling growth. Production now dominates sales, and cost reduction is a key focus for profitability within two to three years. Customized healthcare and dental are set to be the fastest-growing segments.
-
The past year saw significant challenges from weak capital spending, prompting aggressive cost controls while maintaining R&D investment. Growth is expected in high-reliability industrial and healthcare markets, with operational improvements and the Geomagic sale strengthening the financial position.
Fiscal Year 2024
-
Q4 and full-year 2024 results were impacted by a $9M accounting change, but core business met revenue guidance. Cost reduction actions targeting $50M in annualized savings are underway, with 2025 guidance calling for flat to modest revenue growth and break-even EBITDA by year-end.
-
Q3 revenue declined 9% year-over-year due to weak hardware sales, but consumables and healthcare segments showed strong growth. Gross margin was impacted by inventory reserves, and a $144M impairment charge led to a GAAP loss. 2024 revenue is guided at $440–$450M, with profitability improvements expected in 2025.
-
First half 2024 revenues declined 13% year-over-year due to weak printer sales, but sequential growth and margin improvements signal recovery. Full-year revenue is projected at $450–$460 million, with breakeven adjusted EBITDA expected in Q4.